Inclusion Criteria:

1. Patients must have a diagnosis of one of the following histologic types according to
the WHO classification:

- Angioimmunoblastic T-cell lymphoma

- Extranodal NK/T-cell lymphoma, nasal type

- Enteropathy-type T-cell lymphoma

- Hepatosplenic gamma-delta T-cell lymphoma

- Subcutaneous panniculitis-like T-cell lymphoma

- Anaplastic large-cell lymphoma, T/null cell, primary systemic type

- Peripheral T-cell lymphoma, not otherwise characterized

- All biopsy specimens including patients whose diagnosis have been made
outside King Chulalongkorn Memorial Hospital will be reviewed by an expert
hematopathologist at Department of Pathology, King Chulalongkorn Memorial
Hospital.

2. Newly diagnosed, age 15 - 65 years.

3. Complete work up for baseline evaluation and measurement (Appendix B).

4. Patient's free written inform consent.

Exclusion Criteria:

1. Patients with a known hypersensitivity to murine proteins or to any component of
alemtuzumab.

2. Patients who have received prior antilymphoma treatment with chemotherapy or
radiotherapy.

3. Patients with poor performance status (PS; ECOG criteria of 3-4)(Appendix C).

4. Serologic evidence of human immunodeficiency virus exposure.

5. Patients with history of impaired cardiac status or myocardial infarction.

6. Patients with serum creatinine > 1.8 mg/dl, bilirubin > 1.5 times upper limit of
normal range, SGOT or SGPT > 3 times upper limit of normal range, unless due to tumor
involvement.

7. Patients with active uncontrolled infection, active non-malignant gastric or duodenal
ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would
preclude aggressive cytotoxic chemotherapy.

8. Pregnant or lactating women.

9. Serious medical or psychiatric illness which prevent informed consent.

10. Patients who are likely to lost to follow up (e.g., unwilling or difficult to return,
cannot be contacted).